Evidence supporting the use of: Lactobacillus rhamnosus
For the health condition: Urinary Tract Infections

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Lactobacillus rhamnosus has been studied for its potential role in supporting or preventing urinary tract infections (UTIs), particularly in women who experience recurrent infections. The rationale is based on the ability of Lactobacillus species to colonize the vaginal mucosa and compete with uropathogens, thereby restoring or maintaining a healthy microflora that can inhibit the growth and attachment of pathogens like Escherichia coli, the most common cause of UTIs.

Several small clinical trials and in vitro studies have suggested that vaginal or oral administration of L. rhamnosus can help reduce the recurrence of UTIs. A notable randomized controlled trial by Stapleton et al. (2011, Clinical Infectious Diseases) found that intravaginal application of L. rhamnosus GR-1 combined with Lactobacillus reuteri RC-14 modestly reduced the incidence of recurrent UTIs. However, the overall evidence is mixed, with some studies reporting only marginal or non-significant benefits. Systematic reviews, such as those by Grin et al. (2013, Canadian Journal of Urology), conclude that while the approach is promising and biologically plausible, larger and more rigorous clinical trials are necessary to confirm efficacy and determine optimal strains and dosing regimens.

In summary, the use of Lactobacillus rhamnosus for UTI prevention and support is based on preliminary scientific evidence rather than strong, conclusive data. It is not yet a standard of care, but may be considered as an adjunct for some individuals, particularly those seeking non-antibiotic preventive strategies.

More about lactobacillus rhamnosus
More about Urinary Tract Infections